Redline Comparison of Michniak-Kohn Declarations in IPR2018-00608 and IPR2019-00207 Redline Comparison of Gilmore Declarations in IPR2018-00608 and IPR2019-00207 Petitioner’s Notice of Paragraph IV Certification to Patent Owner (February 22, 2019) (truncated) Declaration of Elizabeth B. Hagan in Support of Patent Owner Almirall, LLC’s Motion for Admission Pro Hac Vice International Patent Application Publication No. WO 2011/014627 (“Ahluwalia”) Dina Anderson, Finding a Place for Topical Anti-inflammatory Acne Therapy, Practical Dermatology 17 (July 2009) (“Anderson”) Christin N. Collier et al., The prevalence of acne in adults 20 years and older, 58 J. Am. Acad. Dermtol.

133 (2011) (“Fabbrocini”) Zoe D. Draelos et al., Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris, 46 J. Am. Acad. Dermatol.

783 (2011) (“Tanghetti”) Diane Thiboutot et al., An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients, 59 J. Am. Acad. Dermatol.

Exhibit No. 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 Description M. P. Heffernan et al., A Pilot Study of the Safety and Efficacy of Picolinic Acid Gel in the Treatment of Acne Vulgaris, 156 British J. Dermatol.

548 (2006) (“Heffernan”) Janusz Marcinkiewicz et al., Topical Taurine Bromamine, a New Candidate in the Treatment of Moderate Inflammatory Acne Vulgaris - A Pilot Study, 18 Eur.

Based on the Board call, Almirall may argue against this factor on one of three grounds: that the discovery sought is not relevant; that Dr. Warner did not testify about his declaration in the district court action; and that it seeks confidential information.

The prior art taught that the preparation process can impact both formation of polymer aggregates and the particle size of any undissolved dapsone.

This proceeding is no different from the Taro litigation, as Amneal simply seeks the deposition of Dr. Warner similar to how Almirall made him available previously.

Patent 9,517,219 B2 the Taro action, that request simply seeks the production of a handful of documents (the transcript and any exhibits thereto) and is not burdensome.

This argument would be contrary to the parties’ interactions, as immediately following a few weeks to review Almirall’s POR, supporting declarations, and other exhibits, Amneal made its request.